General description
A cell-permeable quinazoline compound that acts as a highly potent inhibitor of NF-κB transcriptional activation (IC50 = 11 nM in Jurkat cells) and LPS-induced TNF-α production (IC50 = 7 nM in murine splenocytes). Shown to exhibit anti-inflammatory effect on carrageenin-induced paw edema in rat. A 10 mM (1 mg/281 µl) solution of NF-κB Activation Inhibitor (Cat. No. 481407) in DMSO is also available.
A cell-permeable quinazoline compound that acts as a potent inhibitor of NF-κB transcriptional activation (IC50 = 11 nM in Jurkat cells) and LPS-induced TNF-α production (IC50 = 7 nM in murine splenocytes). Does not exhibit cellular cytotoxicity even at concentrations as high as 10 µM. Reported to exhibit anti-inflammatory effects on carregeenin-induced paw edema in rats.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
NF-κB transcriptional activation
Product does not compete with ATP.
Reversible: no
Target IC50: 11 nM against NF-κB transcriptional activation in Jurkat cells
Packaging
Packaged under inert gas
Warning
Toxicity: Toxic (F)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
Tobe, M., et al. 2003. Bioorg. Med. Chem.11, 383.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
- UPC:
- 41116113
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 481406-1MG